Phase i study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis

Oncology

Volumn 79, Issue 3-4, 2011, Pages 269-272

  Ishigami, Hironori ^a   Kitayama, Joji ^a   Kaisaki, Shoichi ^a   Yamaguchi, Hironori ^a   Yamashita, Hiroharu ^a   Emoto, Shigenobu ^a   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cisplatin; Combination chemotherapy; Gastric cancer; Intraperitoneal chemotherapy; Paclitaxel; Phase I study

Indexed keywords

CISPLATIN; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952101627     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323272     Document Type: Article

References (14)

1. Sugarbaker PH, Yonemura Y: Clinical path-way for the management of resectable gastric cancer with peritoneal seeding: best pallia-tion with a ray of hope for cure. Oncology 2000; 58: 96-107. (Pubitemid 30113860)
2. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointes-tinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
3. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishiza-ki T, Kobayashi O, Takiyama W, Toh Y, Na-gaie T, Takagi S, Yamamura Y, Yanaoka K Orita H, Takeuchi M: S-1 plus cisplatin ver-sus S-1 alone for first-line treatment of ad-vanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
4. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furuka-wa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K, ACTS-GC Group: Adjuvant chemothera-py for gastric cancer with S-1, an oral fluoro-pyrimidine. N Engl J Med 2007; 357:1810-1820. (Pubitemid 350044801)
5. Ajani JA, Fairweather J, Dumas P, Patt Y Z, Pazdur R, Mansfield P F: Phase II study of Taxol in patients with advanced gastric car-cinoma. Cancer J Sci Am 1998; 4: 269-274.
6. Ohtsu A, Boku N, Tamura F, Muro K, Shi-mada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21:416-419. (Pubitemid 28366916)
7. Yamaguchi K, Shimamura T, Komatsu Y, Takagane A, Yoshioka T, Saitoh S, Munakata M, Sakata Y, Sato T, Arai T, Saitoh H, East Japan Gastric Cancer Study Group: Phase I-II study of biweekly paclitaxel administra-tion with fixed-dose-rate cisplatin in ad-vanced gastric cancer. Gastric Cancer 2006; 9: 36-43.
8. Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y: Phase II study of biweekly paclitaxel and cisplatin combination chemo-therapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Jpn J Clin Oncol 2007; 37: 501-508. (Pubitemid 47335468)
9. Nagata N, Kimura M, Hirabayashi N, Tu-buraya A, Murata T, Kondo K, Fukuda Y, Ko-bayashi M, Miyashita Y, Nakao A, Sakamoto J: Phase II study of weekly paclitaxel and cis-platin combination therapy for advanced or recurrent gastric cancer. Hepatogastroenter-ology 2008; 55:1846-1850.
10. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M: Phase I feasibility and pharmacologic study of weekly intraper-itoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995; 13: 2961-2967.
11. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43. (Pubitemid 43048949)
12. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Hidemura A, Kaisaki S, Nagawa H: Phase I pharmaco-kinetic study of weekly intravenous and in-traperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 2009; 76:311-314.
13. Ishigami H, Kitayama J, Kaisaki S, Hidemu-ra A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperito-neal paclitaxel combined with S-1 for ad-vanced gastric cancer with peritoneal metas-tasis. Ann Oncol 2010; 21:67-70.
14. Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R: Adjuvant intraperitoneal cispla-tin chemotherapy does not improve long-term survival after surgery for advanced gas-tric cancer. J Clin Oncol 1994; 12:970-974.